Joanna Rhodes, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, discusses the value of measurable residual disease (MRD) in prognosticating outcomes for patients with chronic lymphocytic leukemia (CLL). She mentions several trials (CLL13; NCT02950051, UK FLAIR; ISRCTN01844152, CLARITY; ISRCTN13751862, CAPTIVATE; NCT02910583) which provide evidence for the prognostic value of MRD negativity, including in patients treated with chemoimmunotherapy, and venetoclax-based fixed-duration regimens. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть